Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on Clioquinol in Drug-resistant Childhood Epilepsy
NCT05727943Phase 2Completed
- Sponsor
- KU Leuven
- Start
- Mar 2022
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Clioquinol in epilepsy, sponsored by KU Leuven. Primary endpoints: Responder rate (seizure frequency reduction >50%) at 8 weeks and Percent reduction of seizure frequency at 8 weeks. Started Mar 2022; status: completed.
02
Drugs
Clioquinol
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05727943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727943.